JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Bristol-Myers Squibb Co.

Slēgts

SektorsVeselības aprūpe

46.58 1.35

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

45.69

Max

46.12

Galvenie mērījumi

By Trading Economics

Ienākumi

1.3B

3.8B

Pārdošana

1.1B

12B

P/E

Sektora vidējais

18.414

34.393

EPS

1.46

Dividenžu ienesīgums

5.42

Peļņas marža

30.769

Darbinieki

34,100

EBITDA

1.9B

4.5B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+12.36% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

5.42%

2.54%

Nākamie ieņēmumi

2025. g. 30. okt.

Nākamais dividenžu datums

2025. g. 31. okt.

Nākamais Ex dividenžu datums

2025. g. 3. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2B

93B

Iepriekšējā atvēršanas cena

45.23

Iepriekšējā slēgšanas cena

46.58

Ziņu noskaņojums

By Acuity

35%

65%

113 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Bristol-Myers Squibb Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. jūl. 11:14 UTC

Peļņas

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

2025. g. 2. jūn. 11:48 UTC

Galvenie tirgus virzītāji

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

2025. g. 4. aug. 11:59 UTC

Peļņas

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

2025. g. 31. jūl. 11:54 UTC

Peļņas

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Expected Continued Generic Impact Across Remainder of Legacy Portfolio, as Well as Impacts From U.S. Medicare Part D Redesign >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb: In Back Half of Year, Focused on Advancing Transformational Medicines and Delivering on Our Growth Portfolio and Important Pipeline Opportunities to Shape Our Growth Trajectory >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb: Latest 2Q Includes Net Impact of Loss of 57c/Shr Due to Acquired IPRD Charge Associated With BioNtech Strategic Partnership >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q Gross Margin 72.5% >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q Rev $12.27B >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of BioNTech Acquired IPRD Chg in 2Q >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY

2025. g. 31. jūl. 10:59 UTC

Peļņas

Bristol Myers Squibb 2Q EPS 64c >BMY

2025. g. 12. jūn. 14:20 UTC

Iegādes, apvienošanās, pārņemšana

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

2025. g. 13. maijs 16:48 UTC

Iegādes, apvienošanās, pārņemšana

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

2025. g. 12. maijs 22:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025. g. 12. maijs 18:45 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025. g. 12. maijs 17:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

2025. g. 12. maijs 12:07 UTC

Tirgus saruna

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025. g. 7. maijs 20:09 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

2seventy Bio 1Q Rev $22.9M >TSVT

2025. g. 7. maijs 20:08 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

2seventy Bio 1Q EPS 1c >TSVT

Salīdzinājums

Cenas izmaiņa

Bristol-Myers Squibb Co. Prognoze

Cenas mērķis

By TipRanks

12.36% augšup

Prognoze 12 mēnešiem

Vidējais 51.63 USD  12.36%

Augstākais 65 USD

Zemākais 34 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bristol-Myers Squibb Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

20 ratings

4

Pirkt

15

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 50.57Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

113 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.